

ADVERTISEMENT

Are you connected?



THE LANCET

Home Journals ▾ Specialties ▾ The Lancet Clinic ▾ Global Health ▾ Multimedia ▾ Campaigns ▾ More ▾ Information for ▾

Submit a Paper ▾

THE LANCET



[Login](#) | [Register](#) | [Subscribe](#)

Online First Current Issue All Issues Special Issues Multimedia ▾ Information for Authors

All Content

Search [Advanced Search](#)

< Previous Article

Online First

Next Article >

Access this article on [ScienceDirect](#) ▶

Comment

## Statin-associated muscle symptoms: beware of the nocebo effect

Juan Pedro-Botet , Juan Rubiés-Prat

Published: 02 May 2017

105

DOI: [http://dx.doi.org/10.1016/S0140-6736\(17\)31163-7](http://dx.doi.org/10.1016/S0140-6736(17)31163-7)



Article Info

Summary Full Text Tables and Figures References

Patient-reported statin intolerance, predominantly due to statin-associated muscle symptoms (SAMS), is a common and difficult-to-manage condition affecting millions of patients worldwide.<sup>1</sup> Different expert panels have proposed various definitions and classifications for statin intolerance.<sup>2,3</sup> However, the development of SAMS does not necessarily signify statin intolerance since statin therapy might not always be pharmacologically involved. Moreover, some patients with SAMS might be able to tolerate a lower dose than the dose that leads to

### Article Options

- [PDF \(303 KB\)](#)
- [Email Article](#)
- [Add to My Reading List](#)
- [Export Citation](#)
- [Create Citation Alert](#)
- [Cited by in Scopus \(0\)](#)

### Linked Articles

**ARTICLES**  
**Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-**

SAMS, longer dose intervals, or an alternative statin.

To read this article in full you will need to make a payment

Already registered? Please login.

Log in to Your Account

Login to existing account

Forgot password?

Register  
Create a new account

The Lancet Choice  
Access any 5 articles from The Lancet family of journals

- Full text and PDF access to 5 paywall articles of your choice
- Valid for 365 days from date of purchase
- Find out more about The Lancet Choice

Payment Options

- Purchase this article for \$31.50 USD
  - Online access for 24 hours
  - PDF version can be downloaded as your permanent record

Subscribe to The Lancet  
Purchase a subscription to gain access to this and all other articles in this journal.

Options include:

- Personal online only subscription

Institutional Access  
Visit ScienceDirect to see if you have access via your institution.

Already a print subscriber?  
Claim online access

Have a free trial code?  
Activate your free trial

Scandinavian Cardiac Outcomes Trial—Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase

Popular Articles

| Most Read | Most Cited |
|-----------|------------|
|-----------|------------|

Most read in *The Lancet* within the past 30 days.

ARTICLES  
**Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990–2015: a novel analysis from the Global Burden of Disease Study 2015**

Published: May 18, 2017  
[Open Access](#)

ARTICLES  
**Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial**

Vol. 389, No. 10084  
Published: April 26, 2017  
[Open Access](#)

XXX 18-TRISOMY  
Vol. 278, No. 7211  
Published: November 11, 1961

ARTICLES  
**Smoking prevalence and attributable disease burden in 195 countries and territories, 1990–2015: a systematic analysis from the Global Burden of Disease Study 2015**

Vol. 389, No. 10082  
Published: April 5, 2017  
[Open Access](#)

ARTICLES  
**Estimates and 25-year trends of the global burden of disease attributable to ambient air pollution: an analysis of data from the Global Burden of Diseases Study 2015**

Vol. 389, No. 10082  
Published: April 10, 2017  
[Open Access](#)

## The Lancet Choice



**The Lancet Choice** is a new payment option that gives you the freedom and flexibility to access any 5 premium articles of your choice from across *The Lancet* family of journals - all for a one-off payment of \$49.00 USD.

Simply purchase your Lancet Choice pass from the Summary or Full Text page of an article you wish to access. This will count as the first of 5 article credits, or 'Allowances', and you can use your 4 remaining Allowances to access other articles from any of *The Lancet* journals.

[Find out more about The Lancet Choice](#)

### The Lancet Journals

The Lancet  
The Lancet Child & Adolescent Health  
The Lancet Diabetes & Endocrinology  
The Lancet Gastroenterology & Hepatology  
The Lancet Global Health  
The Lancet Haematology

The Lancet HIV  
The Lancet Infectious Diseases  
The Lancet Neurology  
The Lancet Oncology  
The Lancet Planetary Health  
The Lancet Psychiatry  
The Lancet Public Health  
The Lancet Respiratory Medicine  
EBioMedicine

### Information & Support

About Us  
Information for Authors  
Information for Readers  
The Lancet Careers  
Customer Service  
Contact Us  
Privacy Policy  
Terms and Conditions

### Subscription

Your Account  
Subscription Options  
Existing Print Subscribers

Cookies are set by this site. To decline them or learn more, visit our [Cookies page](#).

*The Lancet* demonstrates its commitment to accessibility by enabling access and optimising the experience for individuals with disabilities and impairments.

